Novartis

Novartis Ireland:

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments.  Novartis is currently conducting over 20 clinical trials in Ireland.  About 105 thousand people of more than 140 nationalities work at Novartis around the world and over 1,200 in Ireland in commercial operations in Dublin and manufacturing in Cork. Find out more at http://www.novartis.ie.

Novartis Team:

Although we do not have the chance to meet in person at this year’s IAD Spring Meeting, we want to reassure you that our team are always here to support you and your patient’s needs. 

If you would like any information on the use of Cosentyx, Cosentyx Patient materials or details about our Cosentyx Patient Support Service please get in touch.  We wish you an enjoyable IAD Meeting and looking forward to seeing you all in person in the near future.

Lorna Rice

Dermatology Hospital Specialist –Leinster & Connacht

Jackie Healy

Dermatology Hospital Specialist –Munster & Connacht

Legal Category: POM Marketing Authorisation Holder: Novartis Europharm Ltd, Vista Building, Elm Park Business Campus, Merrion Rd, Dublin 4, Ireland. Full prescribing information is available upon request from: Novartis Ireland Limited, Vista Building, Elm Park Business Park, Elm Park, Dublin 4. Tel: 012601255 or at http://www.medicines.ie.

Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: drugsafety.dublin@novartis.com or by calling 01 2080 612.

April 2021| IE121622